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Variceal hemorrhage is a lethal complication of cirrhosis, par-ticularly in patients in whom clinical decompensation (i.e., ascites, encepha­lopathy, a previous episode of hemorrhage, or jaundice) has already developed. 
Practice guidelines for the management of varices and variceal hemorrhage1 in cir­
rhosis are mostly based on evidence in the literature that has been summarized and 
prioritized at consensus conferences.2,3 There are three main areas of management: 
primary prophylaxis to prevent a first episode of variceal hemorrhage, treatment of 
the acute bleeding episode, and secondary prophylaxis (prevention of recurrent var­
iceal hemorrhage). 
Nat ur a l His t or y a nd Epidemiol o gy
Gastroesophageal varices are present in almost half of patients with cirrhosis at the 
time of diagnosis, with the highest rate among patients with Child–Turcotte–Pugh 
(hereinafter called Child) class B or C disease (Table 1).4 Development and growth 
of gastroesophageal varices each occur at a rate of 7% per year.5,6 The 1­year rate of 
a first variceal hemorrhage is approximately 12% (5% for small varices and 15% for 
large varices).7 Besides variceal size, red wale marks on varices and advanced liver 
disease (Child class B or C) identify patients at a high risk for variceal hemorrhage.8 
The 1­year rate of recurrent variceal hemorrhage is approximately 60%.9 The 6­week 
mortality with each episode of variceal hemorrhage is approximately 15 to 20%, 
ranging from 0% among patients with Child class A disease to approximately 30% 
among patients with Child class C disease.10-12
Pathoph ysiol o gy a nd Pathoph ysiol o gic a l B a ses  
of Ther a py
Gastroesophageal varices are a direct consequence of portal hypertension that, in 
cirrhosis, results from both increased resistance to portal flow and increased portal 
venous blood inflow. Increased resistance is both structural (distortion of liver 
vascular architecture by fibrosis and regenerative nodules) and dynamic (increased 
hepatic vascular tone due to endothelial dysfunction and decreased nitric oxide bio­
availability).13
When the portal­pressure gradient (the difference between portal­vein pressure 
and hepatic­vein pressure) increases above a certain threshold, collaterals develop at 
sites of communication between the portal and systemic circulations.5 This pro­
cess is modulated by angiogenic factors.14,15 Concomitantly with the formation of 
portosystemic collaterals, portal venous blood inflow increases as a result of splanch­
nic vasodilatation and increased cardiac output.16 Increased portal flow maintains 
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and exacerbates portal hypertension. Gastro­
esophageal varices are the most important col­
laterals, because as pressure and flow increase 
through them, they grow and eventually rupture 
(Fig. 1).
Available therapies for varices and variceal hem­
orrhage can be classified according to whether 
they act on the physiological mechanisms of por­
tal hypertension.
Therapies that Reduce Portal Pressure
Splanchnic vasoconstrictors such as vasopressin 
and somatostatin (and their analogues, octreotide 
and vapreotide) are administered parenterally and 
are therefore restricted to use in an acute care 
setting. Nonselective beta­adrenergic blockers af­
fect portal f low by means of both β1­blockade 
(reduction of cardiac output) and β2­blockade 
(splanchnic vasoconstriction).17 Therefore, non­
selective beta­blockers such as propranolol or na­
dolol are better than selective beta­blockers be­
cause of broader mechanisms of action. They are 
administered orally and are used in the long­term 
treatment of portal hypertension.
Drugs that increase the delivery of nitric oxide 
to the intrahepatic circulation, such as nitrates and 
simvastatin, and drugs that block adrenergic ac­
tivity (e.g., prazosin and clonidine) or that block 
angiotensin (e.g., captopril, losartan, and irbesar­
tan) act by inducing intrahepatic vasodilatation.17 
Unfortunately, venodilators may also cause sys­
temic vasodilatation, with aggravation of sodium 
retention and renal vasoconstriction.18,19 An excep­
tion may be simvastatin, which acts on the dys­
functional intrahepatic endothelium without an 
effect on the systemic circulation.20,21
The combination of vasodilators and splanch­
nic vasoconstrictors, such as the combination of 
nonselective beta­blockers plus nitrates or carve­
dilol (a nonselective beta­blocker with an added 
vasodilatory effect through anti–α1­adrenergic ac­
tivity), has an additive portal pressure–reducing 
effect but can also decrease arterial pressure.22
Notably, none of the drugs mentioned above are 
approved in the United States for the treatment of 
portal hypertension. Their use in patients with 
portal hypertension is therefore considered off­
label.
A shunt connecting the hypertensive portal 
system and low­pressure systemic veins reverses 
portal hypertension; this can be achieved percu­
taneously through the placement of a transjugular 
intrahepatic portosystemic shunt or surgically.
Local Therapies without Portal Pressure–
Reducing Effects
Endoscopic procedures can be used to place elas­
tic bands on variceal columns (variceal ligation) 
or to inject sclerosing agents (variceal sclerother­
apy) or tissue adhesives (variceal obturation) into 
gastroesophageal varices.23 These techniques can 
achieve variceal obliteration (sometimes called 
“eradication”). However, gastroesophageal varices 
will eventually recur; therefore, close endoscopic 
surveillance and retreatment are necessary. Other 
shorter­term temporizing local mea sures include 
balloon tamponade and placement of expandable 
esophageal stents.24
Table 1. Child–Turcotte–Pugh Classification of Cirrhosis.
Clinical and Biochemical Criteria Points*
1 2 3
Encephalopathy None Mild to moderate (grade 1 or 2) Severe (grade 3 or 4)
Ascites None Mild to moderate Large or refractory to diuretics
Bilirubin (mg/dl) <2 2–3 >3
Albumin (g/dl) >3.5 2.8–3.5 <2.8
Prothrombin time†
Seconds prolonged <4 4–6 >6
International normalized ratio <1.7 1.7–2.3 >2.3
* In the Child–Turcotte–Pugh classification system, class A (5 to 6 points) indicates least severe liver disease, class B  
(7 to 9 points) indicates moderately severe liver disease, and class C (10 to 15 points) indicates most severe liver dis-
ease. To convert the values for bilirubin to micromoles per liter, multiply by 17.1.
† Either seconds prolonged or the international normalized ratio is used.
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R isk S tr atific ation for Patients 
w i th Porta l H y pertension
One of the main issues confounding screening of 
and therapeutic studies involving patients with 
cirrhosis is a lack of proper risk stratification. At 
a minimum, patients should be stratified accord­
ing to whether they have compensated or decom­
pensated cirrhosis.25
In patients with compensated cirrhosis (i.e., 
those who do not have ascites, variceal hemor­
rhage, encephalopathy, or jaundice), risk stratifi­
cation starts with an assessment for the presence 
of gastroesophageal varices. Patients with gastro­
esophageal varices have a higher rate of death and 
a greater risk of decompensation than those with­
out gastroesophageal varices.26 The recommended 
method to determine the presence and size of 
gastroesophageal varices is esophagogastrodu­
odenoscopy.1,2,27 Less invasive methods such as 
capsule endoscopy are being investigated and may 
be preferred by patients; however, their accuracy 
in evaluating the presence of varices, red wale 
marks, and variceal size is still suboptimal.27 
Similarly, a ratio of platelet count (per cubic milli­
meter) to spleen size (the maximum bipolar di­
6 col
33p9
AUTHOR:
FIGURE:
RETAKE:
SIZE
4-C H/TLine Combo
Revised
AUTHOR, PLEASE NOTE: 
Figure has been redrawn and type has been reset.
Please check carefully.
1st
2nd
3rd
Garcia-Tsao
1 of 1
ARTIST:
TYPE:
ts
03-04-09JOB: 361xx ISSUE:
Cirrhosis
Increased resistance
to portal flow
(fixed and functional)
Increased portal
pressure
Dilatation of preexisting
vessels
Varices
Variceal growth
Variceal rupture
Increased flow through
varices
Splanchnic
vasodilatation
Increased angiogenic
factors (e.g., VEGF)
Formation of new
vessels
Increased vasodilating
factors (e.g., nitric oxide)
Increased portal
blood inflow
Figure 1. The Pathogenesis of Portal Hypertension, Varices, and Variceal Hemorrhage.
The initial mechanism in the development of portal hypertension in cirrhosis is an increase in vascular resistance to 
portal flow. A subsequent increase in portal venous inflow maintains the portal hypertensive state. Portal hyperten-
sion leads to the formation of portosystemic collaterals, of which the most clinically relevant are gastroesophageal 
varices. The increase in flow through these collaterals, enhanced by the presence of splanchnic vasodilatation and 
increased portal blood inflow, leads to variceal growth and rupture. This process is modulated by angiogenic fac-
tors. VEGF denotes vascular endothelial growth factor.
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ameter in millimeters by ultrasonography) above 
909 has a high negative predictive value (i.e., the 
patient is unlikely to have varices).28 However, this 
ratio requires further validation.29
In patients without varices and in those with 
variceal hemorrhage, measurement of portal pres­
sure with the use of the hepatic venous pressure 
gradient (HVPG) is the best method to stratify 
risk. Portal hypertension is present when the 
HVPG is greater than 5 mm Hg, but it is consid­
ered clinically significant when the HVPG is 
greater than 10 mm Hg, because in patients with­
out varices, this pressure is the strongest predic­
tor of the development of varices,5 clinical decom­
pensation,30 and hepatocellular carcinoma.31 In 
patients with variceal hemorrhage, an HVPG of 
more than 20 mm Hg (measured within 24 hours 
after admission) is the best predictor of a poor 
outcome.32 In contrast, a reduction in the HVPG to 
less than 12 mm Hg or a reduction of more than 
20% from the baseline value is associated with a 
decreased risk of variceal hemorrhage and im­
proved survival.33,34
The HVPG is obtained by means of catheter­
ization of a hepatic vein with a balloon catheter 
through a jugular or femoral vein. Although the 
procedure to obtain the HVPG is simple and safe 
(see the video, available with the full text of this 
article at NEJM.org), it is invasive and its use is not 
widespread in the United States. Standardization 
of the technique through the creation of multi­
society guidelines, certification, and quality con­
trol is needed to help bring the HVPG into wider 
clinical use.3
Measurement of liver stiffness, a technique not 
yet widely available in the United States, is a non­
invasive method that correlates reasonably well 
with the HVPG, particularly at HVPG values below 
10 mm Hg.35 Therefore, it appears to be useful in 
identifying the presence of clinically significant 
portal hypertension. Notably, the presence of va­
rices (or collaterals on imaging studies) indicates 
that clinically significant portal hypertension is 
present.
The Child class or its laboratory components 
(the levels of bilirubin and albumin and the in­
ternational normalized ratio) correlate roughly 
with clinically significant portal hypertension36 
and can be used to stratify risk in both compen­
sated and decompensated cirrhosis.26 In patients 
with variceal hemorrhage, Child class C has been 
associated with an HVPG of more than 20 mm Hg 
and a poor outcome.11 The Model for End­Stage 
Liver Disease score, which is used for organ alloca­
tion in liver transplantation, has been shown to 
predict the development of decompensation in 
patients without varices30 and to predict 6­week 
mortality after variceal hemorrhage.37
Pr e v en tion of Va r ices a nd  
a  Fir s t Va r ice a l Hemor r h age
Patients without gastroesophageal varices or with 
gastroesophageal varices that have never bled are 
at relatively low risk for bleeding and death, and 
therefore, therapies for these patients should be 
the least invasive. In patients without varices, treat­
ment with nonselective beta­blockers is not rec­
ommended because they do not prevent the devel­
opment of varices and are associated with side 
effects.5
In patients with low­risk, small varices (with­
out red wale marks and in the absence of severe 
liver disease), nonselective beta­blockers may de­
lay variceal growth and thereby prevent variceal 
hemorrhage.38 These agents are considered op­
tional, given the limited existing evidence, the 
low­risk setting, and the alternative of periodic 
screening for variceal growth.
In patients with small varices that are associ­
ated with a high risk of hemorrhage (varices with 
red wale marks or varices in a patient with Child 
class B or C disease), nonselective beta­blockers are 
recommended.
In patients with medium or large varices, ei­
ther nonselective beta­blockers or endoscopic var­
iceal ligation can be used, since a meta­analysis 
of high­quality, randomized, controlled trials has 
shown equivalent efficacy and no differences in 
survival.39 The advantages of nonselective beta­
blockers are that their cost is low, expertise is not 
required for their use, and they may prevent other 
complications, such as bleeding from portal hy­
pertensive gastropathy, ascites, and spontaneous 
bacterial peritonitis because they reduce portal 
pressure.33,40,41 The disadvantages of these agents 
include relatively common contraindications and 
side effects (fatigue and shortness of breath) that 
preclude treatment or require discontinuation in 
15 to 20% of patients. The advantages of endo­
scopic variceal ligation are that it can be performed 
at the time of screening endoscopy and that its 
side effects are less frequent. However, specific 
expertise is necessary, and there is potential for 
lethal hemorrhage from postprocedure ulcers.17 
Some centers perform endoscopic variceal liga­
A video showing 
HVPG measure-
ment is available 
at NEJM.org 
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tion in most patients, whereas other centers pre­
fer to use nonselective beta­blockers initially, 
switching to endoscopic variceal ligation in pa­
tients with intolerance or contraindications to 
nonselective beta­blockers; the latter is a rational 
approach. The schedule, doses, goals, and follow­
up of therapies for primary prophylaxis are shown 
in Table 2 (see Fig. 1 in the Supplementary Appen­
dix, available with the full text of this article at 
NEJM.org).
Carvedilol at low doses (6.25 to 12.5 mg per 
day) was compared with endoscopic variceal liga­
tion in a recent randomized, controlled trial.42 
Carvedilol was associated with lower rates of first 
variceal hemorrhage (10% vs. 23%) and had an 
acceptable side­effect profile, unlike endoscopic 
variceal ligation, for which compliance was low 
and the rate of first hemorrhage was at the upper 
end of the range of rates in previous studies.42 
Whether carvedilol is more effective or better toler­
ated than nonselective beta­blockers remains to be 
determined.
Tr e atmen t of Acu te Va r ice a l 
Hemor r h age
The rate of death from acute variceal hemorrhage 
has been decreasing over the past two decades, 
probably as a result of improved general manage­
ment (with prophylactic antibiotics) and more ef­
fective therapies (endoscopic variceal ligation and 
vasoactive drugs).43 Although therapy is not cur­
rently targeted at specific risk groups, recent data 
suggest that in patients at high risk (Child class C 
or an HVPG of >20 mm Hg), the approach should 
be more aggressive.
Patients who have Child class A or B disease or 
who have an HVPG of less than 20 mm Hg have 
a low or intermediate risk and should receive stan­
dard therapy — specifically, the combination of a 
safe vasoconstrictor (terlipressin, somatostatin, or 
analogues such as octreotide or vapreotide, admin­
istered from the time of admission and maintained 
for 2 to 5 days) and endoscopic therapy (preferably 
endoscopic variceal ligation, performed at diag­
nostic endoscopy <12 hours after admission),10,44 
together with short­term prophylactic antibiotics 
(either norfloxacin or ceftriaxone).45,46 The only 
vasoconstrictor currently available in the United 
States is octreotide. In other countries, the choice 
of vasoconstrictor depends on availability and cost. 
Antibiotic prophylaxis with ceftriaxone is rec­
ommended in patients with severe liver disease, 
particularly if they are receiving quinolone pro­
phylaxis, whereas others can receive oral norfloxa­
cin or intravenous ciprofloxacin (Table 3).
Placement of a transjugular intrahepatic por­
tosystemic shunt is currently considered a salvage 
therapy for the 10 to 20% of patients in whom 
standard medical therapy fails (Fig. 2 in the Sup­
plementary Appendix). However, two randomized, 
controlled trials have shown that early placement 
of such a shunt (within 24 to 48 hours after ad­
mission) was associated with significant improve­
ment in survival among high­risk patients (i.e., 
patients with an HVPG >20 mm Hg48 or with 
Child class C disease with a score between 10 
and 13 points49 [Table 1]). Therefore, early place­
Table 2. Primary Prophylaxis against Variceal Hemorrhage.*
Regimen† Dose Goal Duration Follow-up
Propranolol Starting dose of 20 mg  
given orally twice a day
Increase to maximally tolerated 
dose or until heart rate is  
approximately 55 beats/min
Indefinite Ensure heart-rate goals met 
at each clinic visit; no 
need for follow-up  
endoscopy
Nadolol Starting dose of 40 mg  
given orally once a day
Increase to maximally tolerated 
dose or until heart rate is  
approximately 55 beats/min
Indefinite Ensure heart-rate goals met 
at each clinic visit; no 
need for follow-up  
endoscopy
Endoscopic 
variceal ligation
Every 2–4 weeks Obliterate varices Until variceal obliteration 
achieved (usually 2–4 
sessions)
Perform first surveillance  
endoscopy 1–3 mo after 
obliteration, then every 
6–12 mo indefinitely
* Therapies that should not be used as prophylaxis include nitrates alone, endoscopic variceal sclerotherapy, shunt therapy (either transjugu-
lar intrahepatic portosystemic shunt or surgical shunt), nonselective beta-blockers plus endoscopic variceal ligation, and nonselective beta-
blockers plus nitrates.
† Only one of the three regimens should be used.
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ment of a transjugular intrahepatic portosystemic 
shunt could be considered in these patients and, 
although this deserves further investigation, the 
decision to use this approach as salvage therapy 
in this high­risk population should be made 
sooner rather than later. In these patients, the use 
of recombinant factor VII has been found to be of 
little value.12
Gastric varices are present in 20% of patients 
with cirrhosis, either in isolation or in combina­
tion with esophageal varices. Bleeding from fun­
dal varices is more severe and is associated with 
a higher rate of death than bleeding from gastro­
esophageal varices.50 
Endoscopic variceal obturation with the use of 
tissue adhesives such as N­butyl­2­cyanoacrylate 
is more effective than endoscopic variceal liga­
tion in controlling initial hemorrhage and prevent­
ing rebleeding from gastric varices.51,52 A trans­
jugular intrahepatic portosystemic shunt is also 
effective in patients with bleeding fundal varices. 
In a recent randomized, controlled trial in which 
endoscopic variceal obturation was used to con­
trol acute hemorrhage in all patients (with a 93% 
success rate), a transjugular intrahepatic porto­
systemic shunt was more effective than endoscop­
ic variceal obturation in preventing recurrent hem­
orrhage.53 
Even though fundal varices were the source of 
bleeding in less than half the patients included 
in these studies and vasoactive drugs have not 
been investigated, data suggest that endoscopic 
variceal obturation is the best endoscopic tech­
nique to control acute hemorrhage and the tran­
sjugular intrahepatic portosystemic shunt is more 
effective than variceal obturation in preventing 
recurrent hemorrhage. Among tissue adhesives, 
N­butyl­2­cyanoacrylate is not available in the 
United States, and although the off­label use of 
another adhesive, 2­octyl cyanoacrylate, has been 
reported,54 endoscopic variceal obturation requires 
careful attention to technique and is not free of 
serious complications. If an endoscopist with the 
requisite expertise is unavailable, placement of a 
transjugular intrahepatic portosystemic shunt 
should be considered first­line therapy when bleed­
ing is not controlled by vasoactive drugs.
Currently, treatment recommendations apply to 
all patients with variceal hemorrhage. Patients 
with Child class A disease have a good response to 
current therapies, with a minimal risk of death 
(0 to 5%). Whether pharmacologic therapy alone 
would suffice in these patients deserves further 
examination. Strategies are being investigated that 
may improve survival in patients with Child 
class C disease, but new strategies should be in­
vestigated for those at intermediate risk (Child 
class B).
Pr e v en tion of R ecur r en t 
Va r ice a l Hemor r h age
Given the high recurrence rate, patients who sur­
vive an acute variceal hemorrhage should receive 
therapy to prevent recurrence before they are dis­
charged from the hospital. Combination pharma­
cologic therapy (nonselective beta­blockers plus 
nitrates) or combination endoscopic variceal liga­
tion plus drug therapy are warranted because of 
the high risk of recurrence, even though the side 
effects will be greater than those with single­
agent therapy (recommended for primary prophy­
laxis). 
These two strategies were compared in a ran­
domized, controlled trial that showed a signifi­
cantly lower rate of variceal rebleeding with a 
combination of endoscopic variceal ligation and 
drug therapy (nonselective beta­blockers plus ni­
trates) than with drug therapy alone. However, 
the rate of hemorrhage from all sources was not 
significantly different because of bleeding from 
esophageal ulcers induced by endoscopic variceal 
ligation.55 
A meta­analysis showed that rates of rebleeding 
(from all sources and from varices) are lower with 
a combination of endoscopic therapy plus drug 
therapy than with either therapy alone, but with­
out differences in survival.56 Therefore, current 
guidelines recommend the combined use of en­
doscopic variceal ligation and nonselective beta­
blockers for the prevention of recurrent variceal 
hemorrhage, even in patients who have had a re­
current hemorrhage despite treatment with non­
selective beta­blockers or endoscopic variceal li­
gation for primary prophylaxis. In patients who 
are not candidates for endoscopic variceal ligation, 
the strategy would be to maximize portal­pressure 
reduction by combining nonselective beta­blockers 
plus nitrates.
Patients who have rebleeding despite combined 
treatment with endoscopic variceal ligation and 
drugs at the recommended doses and schedule 
(Table 4) should undergo percutaneous placement 
of a transjugular intrahepatic portosystemic shunt 
Copyright © 2010 Massachusetts Medical Society. All rights reserved. 
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or surgical creation of a shunt; the two shunts are 
equally effective (Fig. 3 in the Supplementary Ap­
pendix).57 The need for frequent revision of a 
transjugular intrahepatic portosystemic shunt, re­
ported in a randomized, controlled trial,57 appears 
to have been overcome with the current use of 
coated stents, which have a significantly lower oc­
clusion rate.58 The choice between a transjugular 
intrahepatic portosystemic shunt and surgery will 
therefore depend on local expertise and the pa­
tient’s preference.
The rate of recurrent variceal hemorrhage is 
lowest (approximately 10%) among patients in 
whom the HVPG decreases to less than 12 mm Hg 
or is reduced by more than 20% from the baseline 
value.9,34 Perhaps the most rational approach to 
the prevention of recurrent hemorrhage would be 
to choose therapies on the basis of the HVPG 
response; however, the issue will remain unre­
solved until randomized, controlled trials show 
that HVPG­guided therapy is superior to the cur­
rent empirical treatment.
Other than the HVPG response, therapeutic ap­
proaches in patients who have recovered from var­
iceal hemorrhage are not targeted at specific risk 
groups. Given that the severity of liver disease has 
been consistently shown to be a good predictor of 
recurrent hemorrhage and death, the Child clas­
sification could also be a good way to stratify pa­
tients according to risk. Although patients with 
Child class A disease may require only pharma­
cologic therapy, more aggressive combination 
therapies would be required in patients with a high 
risk (i.e., patients with Child class B or C disease 
and patients on the transplantation list).
Speci a l Si t uations for w hich 
Ther e Is  Limi ted or No E v idence
Portal Hypertensive Gastropathy
Portal hypertensive gastropathy is a portal hyper­
tension–related gastrointestinal mucosal lesion 
characterized by ectatic gastric mucosal vessels 
mostly in the fundus and body of the stomach. 
The presence of gastroesophageal varices and the 
Child class are predictive of portal hypertensive 
gastropathy, whereas its development or its pro­
gression from mild to severe correlates only with 
the Child class.59 Although the prevalence of por­
tal hypertensive gastropathy is higher among pa­
tients who have undergone endoscopic therapy 
(sclerotherapy or endoscopic variceal ligation) than T
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among those who have not,60,61 the clinical course 
is the same. The most common presentation, oc­
curring mainly in patients with severe portal hyper­
tensive gastropathy, is chronic, slow hemorrhage 
resulting in anemia. The initial management con­
sists of iron supplementation and use of nonse­
lective beta­blockers; this therapy has been shown 
in a randomized, controlled trial to be effective 
in preventing recurrent hemorrhage.40 If hemor­
rhage continues and the patient requires frequent 
transfusions, shunt therapy (either a transjugular 
intrahepatic portosystemic shunt or shunt sur­
gery) should be considered.
Associated Portal-Vein Thrombosis 
The development of portal­vein thrombosis is an 
important event in the natural history of advanced 
cirrhosis.62 It is associated with worsening liver 
function, ascites, and variceal hemorrhage. The in­
cidence of portal­vein thrombosis is approximately 
16% per year in patients with advanced liver dis­
ease. Treatment for portal­vein thrombosis in these 
patients (e.g., with anticoagulation, thrombolysis, 
or placement of a transjugular intrahepatic porto­
systemic shunt) is currently determined on a case­
by­case basis.63
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